Company
Hutchmed (China) Ltd
LON:HCM
Hutchmed (China) Ltd is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery, global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. A dedicated organization of over 1,400 personnel has advanced eleven cancer drug candidates from in-house discovery into clinical studies around the world, with its first three oncology drugs now approved
62 stories · page 3 of 4
Hutchison China MediTech kicks off first human trial for potential new cancer drug
HMPL-453 targets fibroblast growth factor receptors, which are central to several biological processes
Hutchison China MediTech half year charts big progress
The group has seven candidates being tested across 25 clinical trials, including four pivotal Phase III studies
Archive
SafeCharge in safe hands
Hutchison China Meditech starts trials of blood cancer drug
Hutchison MediPharma has begun the first-in-human phase one clinical trial of HMPL-689 in Australia
Genel Energy a highlight as stocks advance
A proposed buy-back of bonds and a revised reserves estimate has done wonders for Genel's share price, but airing of dirty laundry has hit Fastjet
Archive
Beaufort Securities Breakfast Alert
Market opening: The FTSE-100 is expected to start this morning's session around 50-points higher. New York: Wall Street ended in the green as robust data on ISM manufacturing and construction spending in the US lifted investor sentiment. Ad
Investments and investor services
Risers & Fallers: AA, Travis Perkins, Shire, ServicePower and Pearson...
Below are the main news-driven share price movements at 4pm.
Risers & Fallers: Anglo American, Minds + Machines, UTV Media, Telit Communications and more...
Below are the main news-driven share price movements at 1pm.
Investments and investor services
London shares end week on high; Shire up on M&A talk
The FTSE100 pushed on throughout the afternoon, ending around 40 points higher to 6,378.